<DOC>
	<DOCNO>NCT01897077</DOCNO>
	<brief_summary>The purpose study determine new method administration peanut sublingual immunotherapy , dissolve peanut film , effective .</brief_summary>
	<brief_title>The Safety Efficacy Peanut Immunotherapy Dissolving Film Peanut Allergy</brief_title>
	<detailed_description>Peanut allergy common problem current treatment . Recent study show success oral sublingual immunotherapy treatment food allergy . Oral treatment , require high dos , associate small appreciable risk systemic reaction . Sublingual immunotherapy , utilizes much small dos , safe constraint inherent available method sublingual administration limit utility method . Typically sublingual immunotherapy food allergy use either fresh food simple liquid extract . These method optimize practicality dwell duration mouth , , thus far , dose limited ability make concentrated extract volume extract apply sublingual space . This study conduct determine dissolve peanut extract film , improve efficacy immunotherapy peanut allergy .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Age 18 50 year Provide sign informed consent Using appropriate birth control subject female child bearing age Are available study duration Healthy Volunteers Only Regularly consume meal size portion ( 5 gram ) peanut least twice per month proceed 6 month Peanut Allergic Subjects Only Have history symptomatic reactivity peanut Have positive skin prick test Have positive oral food challenge peanut cumulative dose less 1 gram peanut protein Have selfinjectable epinephrine available home Have history severe anaphylaxis peanut , define hypoxia , hypotension neurological compromise result ingestion peanut . Have history intubation relate asthma Are pregnant lactate Have viral Upper Respiratory Infection ( URI ) gastroenteritis within 7 day Oral food challenge Have pulmonary function test &lt; 80 % predict ( FEV1 ) clinical history consistent moderate persistent asthma Are currently take great medium dose inhale corticosteroid ( &gt; 500 mcg/day fluticasone fluticasone equivalent ) Are unable discontinue antihistamine 5 day long act 3 day short act prior skin test food challenge Have use systemic corticosteroid within 4 week prior baseline visit Are receive omalizumab , betablocker , Angiotensin Converting Enzyme ( ACE ) inhibitor tricyclic antidepressant therapy . Subjects need omalizumab 6 month . Have history oral cancer . Use oral tobacco ( i.e. , chew tobacco ) Have chronic disease ( asthma , atopic dermatitis rhinitis ) require therapy ( e.g. , heart disease , diabetes ) Have participate interventional study treatment food allergy past 12 month Have history eosinophilic esophagitis Have severe reaction initial double blind placebocontrolled food challenge , define either : Lifethreatening anaphylaxis , Reaction require hospitalization Healthy Volunteers Only History allergy peanut</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Food Allergy</keyword>
	<keyword>Peanut</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>